January 2020 in “Current trends in diagnosis & treatment” The review suggests doctors should carefully weigh risks and benefits of off-label drug use, involve patients in decisions, and calls for better regulations and monitoring.
2 citations
,
October 2004 in “Organic Process Research & Development” The document reviews 20 U.S. patents from July and August 2004 about new drug forms, cancer treatments, aroma chemicals, statin drugs, and various chemical production methods.
2 citations
,
November 2014 in “Pharmaceutical Patent Analyst” Recent legal rulings favored Genentech, Teva, and upheld guidelines for patent term extensions.
12 citations
,
January 2007 in “Acta dermato-venereologica” Europe needs a clear system to watch over cosmetics for safety and to make sure product claims are true.
7 citations
,
April 2017 in “Health Economics, Policy and Law” The document suggests reevaluating the patent system to ensure public benefits from pharmaceutical privileges and to encourage more significant innovations.
1 citations
,
December 2014 Some drugs have gained approval for new uses, while others like tricyclic antidepressants and aspirin show promise but aren't yet approved for these uses.
July 2012 in “EFSA supporting publications” The EFSA maintained its view that spermidine's effect on hair growth is related to disease treatment and does not meet the health claim criteria.
2 citations
,
October 2002 in “American Journal of Nursing” Taking the same medication under different brand names caused harmful side effects.
January 2025 in “International Journal of Advancement in Life Sciences Research” Drug repurposing can be cost-effective but needs more testing for safety and effectiveness.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.